世界のガードナー症候群治療市場 – 2030 年までの業界動向と予測

ガードナー症候群治療市場の分析と規模

ガードナー症候群の発症率は米国では100万人に1人程度で、8000人に1人の割合で発症します。通常、ガードナー症候群の患者は典型的には類表皮嚢胞を患っています。この症状に伴う主なリスク要因は、少なくとも片方の親がこの症候群を患っていることです。この症候群に罹患している人は、結腸がんになるリスクも非常に高くなります。  

データブリッジ市場調査は、2023年から2030年の予測期間におけるガードナー症候群治療市場の成長率を分析しています。ガードナー症候群治療市場の予想CAGRは、上記の予測期間中に約4％になる傾向があります。市場は2022年に186億米ドルと評価され、2030年までに254.6億米ドルにまで成長すると予想されています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、データブリッジ市場調査チームがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

ガードナー症候群治療市場の範囲とセグメンテーション

市場の定義

Gardner syndrome is a rare genetic disorder which usually starts with the growth of benign cancer growth. The syndrome can cause growth on numerous regions in the body. The huge number of tumor is generally found in colon in large numbers. As the age of the individual rises, the tumors also surge in large numbers. This syndrome is caused because of the defect in adenomatous polyposis coli (APC) gene, that initiates the production of APC protein. The essential role of APC protein is to control the cell growth by avoiding the cells from rapid division.   

Gardner Syndrome Treatment Market Dynamics

Drivers

• Rising Cases of Colon Cancer

It can be said that the lifetime risk of developing colorectal cancer is around 1 in 23 (4.3%) for men and 1 in 25 (4.0%) for women. In the U.S., colorectal cancer is the third leading cause of cancer-associated deaths in men and in women, and it is the second most common cause of cancer deaths for both genders. It's anticipated to cause around 52,580 deaths during 2022. It has been witnessed that around 106,180 new cases of colon cancer (54,040 men and 52,140 women) and 44,850 new cases of rectal cancer (26,650 men and 18,200 women) existed in 2021. Thus, this increasing prevalence is demanding higher medications and thus boosting the market growth.

• Increased Diagnosis of Gardner Syndrome

Gardner Syndrome can be diagnosed either through medical examination, full evaluation of medical and familial history and self-reported symptoms, or endoscopy of the lower gastrointestinal (GI) tract. It can also be detected through molecular testing of the blood for screening of genetic mutations known to be linked to the disease. Pre-natal genetic testing can also be done, and if turns out to be positive, endoscopic screenings for polyps is recommended to start as early as 10 years of age. Thus, it boost the market growth.

Opportunities

• Increasing Treatment Methods

Gardner’s syndrome have a huge risk of developing colon cancer, thus the treatment is generally aimed at preventing this. Several medications such as an NSAID or a COX2 inhibitor (celecoxib) may be used to help restrict the growth of colon polyps. Furthermore, treatment also involves close monitoring of the polyps with lower GI tract endoscopy to prevent the malignancy. If 20 or more polyps exist, then it is advised that the colon must be removed to decrease the risk of colon cancer development. Therefore, all these treatment methods are boosting the growth of the market.

Restraints/Challenges

• Complications Associated with Endoscopy

There are many complications that are found to be associated with endoscopy. The complications include grogginess from the sedation, nausea, a feeling of bloating, difficulty swallowing, mild pain where the IV was inserted and sore throat. Thus, all these restrain the market growth.

• High Cost of Treatment

The enormous expenditure that is required for the surgeries and different treatment processes inhibits market growth. Numerous market players make some huge investments in manufacturing new and advanced treatment procedures to increase the recovery process, and in return, the cost is increased.

This gardner syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the gardner syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Gardner Syndrome Treatment Market Scope

The gardner syndrome treatment market is segmented on the basis of cancer type, age and therapeutics. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Cancer Type

• Dilated Cardiomyopathy
• Skeletal Myopathy
• Neutropenia
• Others

Age

• 22 years
• 30-50 years

Therapeutics

• NSAIDS
• COX-2 Inhibitor

Gardner Syndrome Treatment Regional Analysis/Insights

The gardner syndrome treatment market is analyzed and market size insights and trends are provided by cancer type, age and therapeutics as referenced above.

The major countries covered in the gardner syndrome treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market in the forecast period because of the increased awareness among the population base about rare disorders including gardner syndrome and therapeutics.

Asia-Pacific is considered to grow over the coming years because of the increase in point of care diagnostics, novel therapeutics for treatment of the syndrome, huge opportunities in developing markets and different strategic initiatives by several market players.

レポートの国別セクションでは、市場の現在および将来の動向に影響を与える国内市場における個別の市場影響要因と規制の変更についても説明しています。また、国別データの予測分析を提供しながら、グローバルブランドの存在と入手可能性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されています。 

競争環境と世界的ガードナー症候群治療シェア分析

ガードナー症候群治療市場の競争環境は、競合他社ごとに詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性が含まれます。提供されている上記のデータポイントは、ガードナー症候群治療市場に関連する企業の焦点にのみ関連しています。

ガードナー症候群治療市場で活動している主要企業は次のとおりです。

• バイオケムファーマ（インド）
• ザイダスグループ（インド）
• ヴァーナリス（R&D）リミテッド（英国）
• サン・ファーマシューティカル・インダストリーズ（インド）
• サノフィ（フランス）
• ファイザー社（米国）
• ガルデルマラボラトリーズ LP(米国)
• メインファーマグループリミテッド（オーストラリア）
• アコーン オペレーティング カンパニー LLC (米国)
• ジョンソン・エンド・ジョンソン・サービス社（インド）
• メディメトリクス・ファーマシューティカルズ社（米国）
• F.ホフマン・ラ・ロシュ社（スイス）
• マイランNV（米国）
• GSK plc（英国）
• ノバルティスAG（スイス）

SKU-60422